In this special late-breakthrough episode of the ISTH Pulse Podcast, recorded live at #ISTH2025, host Dr. Geoffrey Barnes sits down with Dr. Robert Sidonio, Jr. to discuss groundbreaking results from a Phase 3 clinical trial of rurioctocog alfa pegol in previously untreated patients (PUPs) with severe hemophilia A. Dr. Sidonio breaks down the study design, clinical outcomes, and what sets rurioctocog alfa pegol apart from other FVIII therapies. The conversation explores the potential impact on early treatment strategies, quality of life, and the future of prophylactic care in hemophilia management. Tune in for first-hand insights from one of the leading investigators in the field—and learn how these findings could help shape clinical practice for patients and families around the world.